US Market news
headline news | recent news | latest news | market news | recent topics | stock topics
Global news - chevrons indicate local prediction, arrows show global predictions, circles show importance
NVDA US | Super Micro Computer, one of the hottest AI plays alongside Nvidia, tanks 10% on share offering Shares of Super Micro have surged by more than 900% over the past year as Wall Street looks for stocks to play the AI trend. - cnbc | 19m ago link | |
SLS US | SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET - Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - globenewswire | 20m ago link | |
FATE US | Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor. - globenewswire | 23m ago link | |
MNKD US | 7 For All Mankind Extends Partnership with Tulip to Elevate Customer Engagement Tulip Clienteling is instrumental in driving cross-channel sales and store traffic at 7FAM TORONTO, March 19, 2024 /PRNewswire/ -- Tulip, a leading cloud-based retail customer engagement platform provider, is excited to announce the extension of its partnership with 7 For All Mankind, the... - prnewswire:443 | 28m ago link | |
GNPX US | Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules AUSTIN, Texas, March 19, 2024 /PRNewswire/ -- Genprex, Inc. ('Genprex' or the 'Company') (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive... - prnewswire:443 | 31m ago link | |
NVDA US | Nvidia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . JP Morgan cut the price target for Starbucks Corporation (NASDAQ: SBUX ) from $107 to $100. JP Morgan analyst John Ivankoe maintained an Overweight rating. Starbucks shares gained 1% to close at $91.01 on Monday. See how other analysts view this stock. Guggenheim boosted the price target for The Kroger Co (NYSE: KR ) from $60 to $61. Guggenheim analyst John Heinbockel maintained a Buy rating. Kroger shares rose 0.2% to close at $56.19 on Monday. See how other analysts view this stock . Baird increased Micron Technology, Inc. (NASDAQ: MU ) price target from $ $78 to $115. Baird analyst Tristan Gerra maintained a Neutral rating. Micron shares rose 0.6% to close at $93.78 on Monday. See how other analysts view this stock . Leerink Partners raised the price target for F - benzinga | 32m ago link | |
ATOS US | Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patient who received neoadjuvant and adjuvant (Z)-endoxifen therapy under an FDA-approved 'expanded access' program has completed five years of treatment. As of the date of this press release, the patient remains cancer-free and has reported no significant safety or tolerability issues over the course of her treatment. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. - globenewswire | 37m ago link | |
INUV US | Inuvo Launches Enhanced IntentKey Insights Dashboard Enhanced reporting facilitates impactful client conversations and informed decision making regarding audiences across the marketing funnel Enhanced reporting facilitates impactful client conversations and informed decision making regarding audiences across the marketing funnel - globenewswire | 37m ago link | |
TSLA US | Tesla Stock Trades Lower Premarket: What's Weighing Down On EV Giant Today Tesla, Inc. (NASDAQ: TSLA ) shares fell in premarket trading on Tuesday after rallying over 6% in the previous session. Tech optimism, bargain-hunting and the scepter of vehicle price hikes supported the stock on Monday after it dipped to a 10-month low of $160.51 (intraday) last Thursday. Sentiment appears to have reversed course, as the stock is left to contend with a few negative catalysts. Data released from China showed that weekly insurance registrations for Tesla electric vehicles fell 6.8% week-over-week to 12,300 ... Full story available on Benzinga.com - benzinga | 47m ago link | |
TSLA US | Where Will Tesla Stock Be in 3 Years? Lower profits have driven the stock lower. Is this temporary or a sign things have changed? - fool | 51m ago link | |
NVDA US | Nvidia '1-2 Steps Ahead of Competitors' After Blackwell GPU Reveal At GTC 2024, Analyst Says March 18 marked a significant event for Nvidia Corp (NASDAQ: NVDA ). The company took center stage during its GPU Technology Conference (GTC 2024), revealing pivotal updates and advancements across its accelerated computing landscape . The event, however, didn’t move the market for Nvidia on Monday, with the stock closing the trading day up 0.70%. It did, however, dip by 1.42% in post-market. The Nvidia Analyst: JPMorgan analyst Harlan Sur reiterated an Overweight rating on Nvidia stock with a price target of $850 a share. “NVIDIA is well positioned to continue to benefit from major secular trends in AI, high-performance computing, gaming, and autonomous vehicles, in our view,” said Sur. Also Read: ‘Nothing Short Of Amazing:’ Nvidia Analysts Praise AI Chipmaker’s GTC Unveilings, But Stock Dips As Investors Digest News The Nvidia Thesis – post GTC 2024 Reveal Sur shared insights from the event, shedding light on the traj - benzinga | 52m ago link | |
SEEL US | Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) NEW YORK, March 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ('Seelos'), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase... - prnewswire:443 | 52m ago link | |
HUYA US | What's Going On With HUYA Shares Today? HUYA Inc (NYSE: HUYA ) shares are trading lower after it reported fourth-quarter FY23 revenue of $215.5 million, beating the consensus of $210.04 million . The Chinese game live-streaming platform’s adjusted loss per ADS of $(0.11) was better than the consensus loss of $(0.12) . Live streaming revenues declined to RMB1.34 billion ($189.2 million) from RMB1.98 billion the prior year quarter, owing to the soft macro and industry environment and proactive business adjustments. Meanwhile, advertising and other revenues increased by 40.5% Q/Q and 29.2% Y/Y to $26.2 million, led by game advertising and distribution revenue growth. Also Read : Full story available on Benzinga.com - benzinga | 57m ago link | |
PRFT US | Where Perficient Stands With Analysts Analysts' ratings for Perficient (NASDAQ: PRFT ) over the last quarter vary from bullish to bearish, as provided by 4 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 2 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Perficient, presenting an average target of $69.5, a high estimate of $77.00, and a low estimate of $65.00. Surpassing the previous average price target of $69.00, the current average has increased by 0.72%. Understanding Analyst Ratings: A Comprehensive Breakdown The standing of Perficient among financial experts becomes - benzinga | 1h ago link | |
INFY US | Beyond The Numbers: 4 Analysts Discuss Infosys Stock In the preceding three months, 4 analysts have released ratings for Infosys (NYSE: INFY ), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 0 0 Analysts have recently evaluated Infosys and provided 12-month price targets. The average target is $21.25, accompanied by a high estimate of $22.00 and a low estimate of $20.00. Marking an increase of 18.06%, the current average surpasses the previous average price target of $18.00. Decoding Analyst Ratings: A Detailed Look The standing of Infosys among financial experts is revealed throu - benzinga | 1h ago link | |
LLY US | Should You Pick Eli Lilly Stock After A 4x Rise In Three Years? This can primarily be attributed to a significant 236% rise in the companys P/S ratio to 21x now, versus 6x in 2020. - forbes | 1h ago link | |
FATE US | Evaluating Fate Therapeutics: Insights From 5 Financial Analysts 5 analysts have expressed a variety of opinions on Fate Therapeutics (NASDAQ: FATE ) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 3 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated Fate Therapeutics and provided 12-month price targets. The average target is $7.6, accompanied by a high estimate of $10.00 and a low estimate of $7.00. This current average reflects an increase of 68.89% from the previous average price target of $4.50. Interpreting Analyst Ratings: A Closer Look The analysis of recent analyst actio - benzinga | 1h ago link | |
SNPS US | Synopsys Strengthens Polaris Software Integrity Platform with New Dynamic Security Testing Capabilities Cloud-based dynamic analysis offering optimized for modern web applications, DevSecOps workflows SUNNYVALE, Calif., March 19, 2024 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS) today announced the availability of Synopsys fAST Dynamic, a new dynamic application security testing (DAST)... - prnewswire:443 | 1h ago link | |
MERU US | Meru Health puts 100% of fees at risk Meru Health is guaranteeing industry-leading outcomes, access and engagement with a new value-based pricing structure SAN MATEO, Calif., March 19, 2024 /PRNewswire/ -- Meru Health, a leading virtual-care provider pioneering a lifestyle medicine approach to mental health care, is offering... - prnewswire:443 | 1h ago link | |
COCP US | Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial - globenewswire | 1h ago link | |
LVS US | The Fontainebleau Las Vegas Is Serving Some Of Sin Citys Best Cocktails Beverage director Juyoung Kang ensures that visitors drink well across 36 bars and restaurants, including high-end steakhouses, tequila bars and jazz lounges. - forbes | 1h ago link | |
NVDA US | Nvidia unveils powerful chip in push to extend dominance in AI market Chief executive Jensen Huang claims Blackwell GPUs are substantially faster than its market-leading AI hardware - ft | 1h ago link | |
ACOM US | Ancestry Through FoodFive Cookbooks To Add To Your Shelves Today The five women celebrated here have not only produced stunning cookbooks that would whet anyones appetite, theyve done so by digging into family history. - forbes | 1h ago link | |
NVDA US | Nvidia stock slides in premarket trading after unveiling new AI chip Nvidia sharesdipped in premarket trading after the dominant AI chip supplier unveiled its latest flagship product that is expected to further cement its lead in the industry. - globalnews ca | 1h ago link | |
MU US | MU Pre-Earnings Analysis: Is Micron Technology a Strong Buy? In its most recent quarter, Micron Technology (MU) broke a five-quarter streak of revenue declines, signaling a much-awaited positive growth. However, it also observed a waning in cash reserves. With... - feedburner | 1h ago link | |
BDX US | Cell Culture Market size is set to grow by USD 17.74 bn from 2023-2027, Agilent Technologies Inc., Avantor Inc. & Becton Dickinson and Co., and more to emerge as Some of the Key Companies c- Technavio NEW YORK, March 19, 2024 /PRNewswire/ -- The global cell culture market size is estimated to grow by USD 17.74 bn from 2023 to 2027, according to Technavio. The market is estimated to grow at a CAGR of almost 11.3% during the forecast period. North America held the largest share of the... - prnewswire:443 | 1h ago link | |
LLY US | Did Novo Nordisk Just Get a Jump on Eli Lilly? A recent FDA announcement may have just put one company in the lead. - fool | 1h ago link | |
AAPL US | Amid Rumors of a Deal With Rivian, Apple Acquired This Artificial Intelligence (AI) Start-Up Instead Apple's AI vision is becoming more clear with its recent acquisition of DarwinAI. - fool | 1h ago link | |
MU US | What's Going On With Micron Stock? Micron Technology expects to increase its product sales over the next few years. - fool | 1h ago link | |
NVDA US | Nvidia Stock Is a High-Risk, High-Reward Investment Nvidia has delivered a phenomenal performance in recent quarters. However, investors should not forget that Nvidia's business is volatile. - fool | 1h ago link | |
RRGB US | Gourmet Ice Cream Market size to increase by USD 8851.79 million between 2022 to 2027, Market Segmentation by Product and Geography- Technavio NEW YORK, March 19, 2024 /PRNewswire/ -- The global gourmet ice cream market size is estimated to grow by USD 8851.79 million from 2023 to 2027, according to Technavio. The market is estimated to grow at a CAGR of over 14.32% during the forecast period. The gourmet ice cream market... - prnewswire:443 | 1h ago link | |
NTN US | Gilat Unveils Cloud and 5G NTN Evolution Strategy for SkyEdge IV PETAH TIKVA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT , TASE: GILT)), a worldwide leader in satellite networking technology, solutions, and services, announced today its Cloud and 5G NTN evolution strategy to support Satellite Operators and service providers. 'The satellite communications industry is moving towards digital transformation with the impending shift to Cloud and 5G Non-Terrestrial Networks (NTN). This evolution promises standard ubiquitous connectivity across terrestrial and non-terrestrial networks, a multi-vendor open ecosystem for the satcom industry, and new revenue streams from new use cases,' said Hagay Katz, Chief Product and Marketing Officer. 'As we embark on this exciting journey, it's crucial to focus on efficiency, adaptability, and strategic evolution. Here at Gilat, we have analyzed the key considerations for a seamless evolution to Cloud, 5G NTN and digital interfaces (DIFI), allowing harmonious integration - benzinga | 2h ago link | |
AAPL US | Apple's AI Focus Could Boost Revenue By 6% But May Pose This Near-Term Headwind, Says Munster Amid Google Licensing Rumors Reports of Apple, Inc. (NASDAQ: AAPL ) launching its own AI model and discussing licensing a foundation model with Google and OpenAI illustrate a significant shift in the iPhone maker’s growth strategy, according to Deepwater Asset Management Managing Partner Gene Munster in a note on Monday. Rare Development: Munster notes that after the cancellation of Project Titan, Apple is now considering a rare move for the company – licensing another company’s tech stack. Pulling the plug on the car project offers Apple two advantages, he said. This decision would free up $4 billion to $5 billion annually, approximately 11% of the company’s overall R&D spend, for artificial general intelligence (AGI), and also allow the company to sharpen its focus on AGI. “Apple knows it needs to move fast and is exploring all options when it comes to integrating generative AI into their products - benzinga | 2h ago link | |
DENN US | Denny Hamlins Bristol Win Sets The Stage For A Shot At The Cup Title Denny Hamlin is confident as ever after his big win at Bristol. The Joe Gibbs Racing veteran is Nascar's winingest driver without a championship and that may change. - forbes | 2h ago link | |
FSLY US | Massive News for Fastly Stock Investors Fastly's revenue is increasing by double-digits, but that's not enough for stock market investors. - fool | 2h ago link | |
MOD US | Modine Gains UL Safety Certification for Indoor Air Quality Solutions Achieving UL60335 certification positions technology and indoor air quality leader to help partners comply with new refrigerant safety standard. RACINE, Wis., March 19, 2024 /PRNewswire/ -- Modine (NYSE: MOD), a technology and indoor air quality leader in the HVAC industry, is dedicated... - prnewswire:443 | 2h ago link | |
SYBX US | Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. - globenewswire | 2h ago link | |
NVDA US | Is NVIDIA the source/fuel of AI? Im not sure how those AIs work completely but there is one certain thing that those AIs using GPU and data. For the data part we have Azure, AWS and most of the big companies have their own cloud/storage i dont know how is the manufacturing process and what is the requirements. In GPU part we have APPL, NVIDIA, AMD and Intel(newbie). AMD is a good company too but i didnt use their GPUs i guess they are good at CPUs. And for the APPL they have GPU too but not like NVIDIA. Im sure that those companies producing special products for AIs and big companies.If there is anyone who knows how that works please let me know. If that is the case i guess NVIDIA is so good stock for the long-term. submitted by /u/Time-Garbage444 [link] [comments] - reddit | 2h ago link | |
TSLA US | Jim Cramer Weighs In On Tesla's Potential After Stock Gained Over 6% On Monday: 'Not A Fan Of It, But Not Against It' CNBC’s “Mad Money” host Jim Cramer gave his insights on Tesla Inc. (NASDAQ: TSLA ) as the stock observed an over 6% jump following the announcement of increasing the price of Model Y. What Happened : Tesla’s stock rose following the announcement of a price hike for its Model Y cars, The price increase is expected to come into effect in April. Cramer commented on the stock’s performance, stating “The stock is reacting positively. … It's just been the worst stock in the [S&P 500]. Totally understand. Not a fan of it, but not against it,” reported CNBC on Tuesday. See Also: Whopping $33.8 Million Worth Of Dogecoin Shifted To Robinhood And People Suspect This Person Could Be Behind It Why It Matters : Tesla, once a high flyer, has seen its stock performance dwindle in 2024. The company, which was among the top EV producers, has experienced a sharp decline in its stock value over the last three months. This decl - benzinga | 2h ago link | |
NVDA US | Novo Foundation,Foundation behind maker of Ozempic, and Nvidia Team Up to Build Danish AI Supercomputer Gift article This could springboard the stock price over the long term with a tendency towards a sharp exponential curve once the effects of AI powered research take hold. Bullish on NVO and NVDA. submitted by /u/digital_soapbox [link] [comments] - reddit | 2h ago link | |
GBTC US | Ethereum traders spotted making $900M move: Imminent rebound ahead? Ethereum derivatives market data shows that long traders are covering their position rather than exit. Here's how it could trigger ETH price rebound. - btcmanager | 2h ago link | |
GBTC US | Solana a better version of Ethereum? Arthur Hayes has this to say Hayes believes that Solana can hit $5K-$10K; hence, could offer a great opportunity for those who missed ETH when it was cheap. - ambcrypto | 2h ago link | |
MA US | Visa and Mastercard Are Phenomenal, but Is This a Better Warren Buffett Stock to Buy Right Now? The Oracle of Omaha is still bullish on another top financial stock. - fool | 2h ago link | |
GBTC US | Best Cardano Alternatives: Top 3 Cryptos Under $1 That Can Replace ADA in 2024 Cardano is one of the biggest blockchain projects in the world. With a Market Cap of over $23 Billion, the project was once among the leading players in the decentralized world. However, it has failed to live up to its expectations. The Cardano (ADA) community has expressed concerns about blockchain scalability and the lack of […] The post Best Cardano Alternatives: Top 3 Cryptos Under $1 That Can Replace ADA in 2024 appeared first on TechBullion . - techbullion | 2h ago link | |
STNE US | DLocal Posts Mixed Q4 Results, Joins StoneCo, Beyond Meat And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Tuesday. Shares of DLocal Limited (NASDAQ: DLO ) fell sharply in today’s pre-market trading after the company reported mixed fourth-quarter financial results, issued guidance and announced a new CFO . DLocal reported quarterly earnings of 10 cents per share which missed the analyst consensus estimate of 15 cents by 33.33%. The company reported quarterly sales of $188 million, beating the analyst consensus estimate of $173.686 million, according to data from Benzinga Pro . The company announced the appointment of Mark Ortiz as dLocal’s Chief Financial Officer, effective April 15. DLocal shares dipped 13.3% to $15.77 in ... Full story available on Benzinga.com - benzinga | 3h ago link | |
CVX US | ExxonMobil Continues to Find Oil in a Place Chevron Really Wants to Be Exxon made its latest discovery offshore Guyana. - fool | 3h ago link | |
RDFN US | Real Estate Commissions Are About to Get Much Cheaper. Here's How Zillow, Redfin, and Opendoor Could Be Affected. There are some major changes on the way later in 2024 and real estate commissions could plunge. - fool | 3h ago link | |
FENC US | Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Companys financial and business results. - globenewswire | 3h ago link | |
ADBE US | Down 14% In The Last Trading Session, Where Is Adobe Stock Headed? Adobes stock (NASDAQ: ADBE) has lost 17% in 2024 as compared to the 7% rise in the S&P500 index over the same period. - forbes | 3h ago link | |
AAPL US | iOS 17 Cheat Sheet: All Your Questions About the iPhone Update Answered Have a question about a new feature or an upcoming update? Here's what to know. - feed cnet | 3h ago link |